Teneligliptin Hydrobromide Entèmedyè CAS 401564-36-1 Pite> 99.5% (HPLC) Faktori
Pwovizyon pou Teneligliptin Hydrobromide ki gen rapò ak entèmedyè ak pite segondè
Teneligliptin Hydrobromide CAS 906093-29-6
1-(3-Methyl-1-Phenyl-5-Pyrazolyl) piperazin CAS 401566-79-8
Teneligliptin Hydrobromide Entèmedyè CAS 401564-36-1
| Non Chimik | (2S) -4-Oxo-2-(3-thiazolidinylcarbonyl) -1-pyrrolidinecarboxylic asid tert-butil ester |
| Sinonim | (S)-tèt-Butil 4-oxo-2-(tiazolidin-3-karbonil) pirolidin-1-karboksilat;3-((S)-1-tèt-butoxicarbonyl-4-oxo-2-pyrrolidinylcarbonyl)-1,3-tiazolidin;(2S) -4-oxo-2-(1,3-thiazolidin-3-ylcarbonyl) pirrolidin-1-karboxylate;Teneligptin Entèmedyè B |
| Nimewo CAS | 401564-36-1 |
| Nimewo CAT | RF-1818 |
| Estati Stock | Nan Stock, Pwodiksyon Echèl Jiska Tòn |
| Fòmil molekilè | C13H20N2O4S |
| Pwa molekilè | 300.37 |
| Dansite | 1.305 |
| Mak | Ruifu Chimik |
| Atik | Estanda enspeksyon | Rezilta yo |
| Aparans | Solid koulè blan ak krèm | Konfòme |
| Idantifikasyon | IR;HPLC RT | Konfòme |
| Pèt sou siye | <1.00% | 0.20% |
| Sibstans ki gen rapò | Nenpòt sèl enpurte <0.50% | 0.24% |
| Enpurte total <0.50% | 0.39% | |
| Esè | 99.5% ~ 102.0% (Sou baz sèk) | 99.8% |
| Enantiomeric Pite | >99.5% | 99.9% |
| Sulfated Ash | <0.20% | 0.02% |
| Tès Creole | Enterprise Standard | |
| Itilizasyon | Entèmedyè nan Teneligliptin Hydrobromide (CAS: 906093-29-6) | |
Pake: Boutèy, sak papye aliminyòm, 25kg / tanbou katon, oswa selon kondisyon kliyan an
Kondisyon Depo:Sere nan resipyan ki fèmen nan yon kote ki fre ak sèk;Pwoteje kont limyè ak imidite
(2S)-4-Oxo-2-(3-thiazolidinylcarbonyl)-1-pyrrolidinecarboxylic asid tert-butil ester (CAS: 401564-36-1) se yon entèmedyè ki itilize pou prepare dipeptidyl peptidase IV (DPP-IV) inibitè, entèmedyè nan Teneligliptin Hydrobromide (CAS: 906093-29-6).Teneligliptin se yon inibitè DPP-4 ki te apwouve nan Japon an 2012 pou tretman dyabèt tip II.Li te dekouvri ak devlope pa Mitsubishi Tanabe Pharma sou non komèsyal Tenelia®.Menm jan ak lòt inibitè DPP-4 commercialisés, Teneligliptin te byen tolere nan tout etid ak dòz QD te pwodwi yon aksyon inhibition ki dire lontan kont DPP-4 ak yon ogmantasyon nan nivo aktif GLP-1, ak pousantaj ki ba anpil nan eskresyon ren.
